Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neurosurgery ; 85(2): E226-E232, 2019 08 01.
Artigo em Inglês | MEDLINE | ID: mdl-30325449

RESUMO

BACKGROUND: Perioperative steroid protocols for patients undergoing transsphenoidal surgery (TSS) for pituitary pathology vary by institution. OBJECTIVE: To assess the safety of withholding glucocorticoids in patients undergoing TSS. METHODS: Patients with an intact hypothalamic-pituitary-adrenal (HPA) axis undergoing TSS for a pituitary tumor at the same academic institution between 2012 and 2015 were randomized to either receive 100 mg of intravenous hydrocortisone followed by 0.5 mg of intravenous dexamethasone every 6 h for 4 doses (STER, n = 23) or to undergo surgery without steroids (NOSTER, n = 20). Postoperative cortisol levels were then used to determine the need for glucocorticoids after surgery. Data regarding postoperative cortisol levels, hospital stay length, and complications were collected. RESULTS: Mean postoperative 8 am cortisol levels were higher in the NOSTER group compared to the STER group (745 ± 359 nmol/L and 386 ± 193 nmol/L, respectively, P = .001) and more patients were discharged on glucocorticoids in the STER group (42% vs 12%, P = .07). There was no difference in the incidence of postoperative complications, including hyperglycemia, diabetes insipidus, or permanent adrenal insufficiency. Permanent adrenal insufficiency occurred in 8% of patients. CONCLUSION: Perioperative steroids can be safely withheld in patients with an intact HPA axis undergoing TSS. Although administration of perioperative glucocorticoids does not appear to increase the risk of complications, it may interfere with assessment of the HPA axis after surgery.


Assuntos
Dexametasona/uso terapêutico , Glucocorticoides/uso terapêutico , Hidrocortisona/uso terapêutico , Cuidados Intraoperatórios/métodos , Neoplasias Hipofisárias/cirurgia , Suspensão de Tratamento/estatística & dados numéricos , Insuficiência Adrenal/sangue , Adulto , Feminino , Humanos , Hidrocortisona/sangue , Hiperglicemia/complicações , Sistema Hipotálamo-Hipofisário/fisiologia , Tempo de Internação/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Alta do Paciente , Sistema Hipófise-Suprarrenal/fisiologia , Complicações Pós-Operatórias/etiologia , Estudos Prospectivos , Adulto Jovem
2.
PLoS One ; 13(2): e0192441, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29466430

RESUMO

We previously demonstrated that infusion of an intestinal peptide called xenin-25 (Xen) amplifies the effects of glucose-dependent insulinotropic polypeptide (GIP) on insulin secretion rates (ISRs) and plasma glucagon levels in humans. However, these effects of Xen, but not GIP, were blunted in humans with type 2 diabetes. Thus, Xen rather than GIP signaling to islets fails early during development of type 2 diabetes. The current crossover study determines if cholinergic signaling relays the effects of Xen on insulin and glucagon release in humans as in mice. Fasted subjects with impaired glucose tolerance were studied. On eight separate occasions, each person underwent a single graded glucose infusion- two each with infusion of albumin, Xen, GIP, and GIP plus Xen. Each infusate was administered ± atropine. Heart rate and plasma glucose, insulin, C-peptide, glucagon, and pancreatic polypeptide (PP) levels were measured. ISRs were calculated from C-peptide levels. All peptides profoundly increased PP responses. From 0 to 40 min, peptide(s) infusions had little effect on plasma glucose concentrations. However, GIP, but not Xen, rapidly and transiently increased ISRs and glucagon levels. Both responses were further amplified when Xen was co-administered with GIP. From 40 to 240 min, glucose levels and ISRs continually increased while glucagon concentrations declined, regardless of infusate. Atropine increased resting heart rate and blocked all PP responses but did not affect ISRs or plasma glucagon levels during any of the peptide infusions. Thus, cholinergic signaling mediates the effects of Xen on insulin and glucagon release in mice but not humans.


Assuntos
Glucagon/metabolismo , Intolerância à Glucose/sangue , Insulina/metabolismo , Neurotensina/farmacologia , Polipeptídeo Pancreático/metabolismo , Receptores Colinérgicos/metabolismo , Transdução de Sinais , Adulto , Atropina/administração & dosagem , Atropina/farmacologia , Glicemia/metabolismo , Estudos Cross-Over , Feminino , Polipeptídeo Inibidor Gástrico/administração & dosagem , Frequência Cardíaca/efeitos dos fármacos , Humanos , Secreção de Insulina , Masculino , Pessoa de Meia-Idade , Neurotensina/administração & dosagem
3.
Peptides ; 82: 76-84, 2016 08.
Artigo em Inglês | MEDLINE | ID: mdl-27288245

RESUMO

Xenin-25 (Xen) is a neurotensin-related peptide secreted by a subset of enteroendocrine cells located in the proximal small intestine. Many effects of Xen are mediated by neurotensin receptor-1 on neurons. In healthy humans with normal glucose tolerance (NGT), Xen administration causes diarrhea and inhibits postprandial glucagon-like peptide-1 (GLP-1) release but not insulin secretion. This study determines (i) if Xen has similar effects in humans with Roux-en-Y gastric bypass (RYGB) and (ii) whether neural pathways potentially mediate effects of Xen on glucose homeostasis. Eight females with RYGB and no history of type 2 diabetes received infusions with 0, 4 or 12pmol Xen/kg/min with liquid meals on separate occasions. Plasma glucose and gastrointestinal hormone levels were measured and insulin secretion rates calculated. Pancreatic polypeptide and neuropeptide Y levels were surrogate markers for parasympathetic input to islets and sympathetic tone, respectively. Responses were compared to those in well-matched non-surgical participants with NGT from our earlier study. Xen similarly increased pancreatic polypeptide and neuropeptide Y responses in patients with and without RYGB. In contrast, the ability of Xen to inhibit GLP-1 release and cause diarrhea was severely blunted in patients with RYGB. With RYGB, Xen had no statistically significant effect on glucose, insulin secretory, GLP-1, glucose-dependent insulinotropic peptide, and glucagon responses. However, insulin and glucose-dependent insulinotropic peptide secretion preceded GLP-1 release suggesting circulating GLP-1 does not mediate exaggerated insulin release after RYGB. Thus, Xen has unmasked neural circuits to the distal gut that inhibit GLP-1 secretion, cause diarrhea, and are altered by RYGB.


Assuntos
Diabetes Mellitus Tipo 2/tratamento farmacológico , Diarreia/metabolismo , Insulina/metabolismo , Neurotensina/administração & dosagem , Adolescente , Adulto , Idoso , Glicemia , Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/patologia , Diarreia/induzido quimicamente , Diarreia/fisiopatologia , Feminino , Derivação Gástrica/métodos , Polipeptídeo Inibidor Gástrico/metabolismo , Glucagon/metabolismo , Peptídeo 1 Semelhante ao Glucagon/metabolismo , Glucose/metabolismo , Humanos , Secreção de Insulina , Masculino , Pessoa de Meia-Idade , Neuropeptídeo Y/metabolismo , Neurotensina/efeitos adversos , Neurotensina/metabolismo , Polipeptídeo Pancreático/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...